Login / Signup

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.

Valentina BurgioMassimo IavaroneGiovanni Giuseppe Di CostanzoFabio MarraSara LonardiEmiliano TamburiniPiscaglia FabioGianluca MasiCiro CelsaFrancesco Giuseppe FoschiMarianna SillettaDaniela Caterina AmorusoMargherita RiminiMariangela BruccoleriRaffaella TortoraClaudia CampaniCaterina SoldàMassimo Giuseppe ViolaAntonella ForgioneFabio ContiFrancesca SalaniSilvia CataneseCarmelo Marco GiacchettoClaudia FulgenziCarmine CoppolaPietro LamperticoAntonio PellinoGabriele RancatoreGiuseppe CabibboFrancesca RattiFederica PedicaAngelo Della CorteMassimo ColomboFrancesco De CobelliLuca AldrighettiStefano CascinuStefano Cascinu
Published in: Cancer management and research (2021)
Our study highlighted for the first time the efficacy and safety of lenvatinib in an Italian cohort of patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • electronic health record
  • machine learning
  • liver metastases